Why Crinetics Stock Soared 99% This Week
Crinetics Pharmaceuticals (NASDAQ:CRNX) shares have climbed 99% just this week, from $42.03 at Monday’s close, to $83.54 earlier today. The simple reason: Vertex Pharmaceuticals (NASDAQ:VRTX) agreed…
Read the full articleYou might also wanna read
Vertex Is Paying a 102% Premium to Acquire Crinetics for $10 Billion. Here's Whether the Deal Is Worth It.
This buy gives Vertex both a recently-commercialized drug, and a very strong lead candidate.
STAT+: Vertex acquires Crinetics Pharmaceuticals for $10 billion as biotech M&A booms
Vertex Pharmaceuticals will spend $10 billion to acquire Crinetics Pharmaceuticals and its drug for a rare endocrine disorder, the companies
Vertex Is Buying Crinetics for $10 Billion. Here's What Investors Need to Know.
The drugmaker is paying up for a new growth engine. Is the price disciplined?
Vertex, in its largest-ever deal, acquires endocrine disease specialist Crinetics for $10B
Vertex Pharmaceuticals has struck a $10 billion deal—its largest ever—to acquire endocrine disease specialist Crinetics Pharmaceuticals. The
STAT+: Pharmalittle: We’re reading about a $10 billion Vertex deal, the pace of FDA drug approvals, and more
Vertex Pharmaceuticals will spend $10 billion to acquire Crinetics Pharmaceuticals and its drug for a rare endocrine disorder
Joele Frank Works Crinetics' $8.8B Deal
Joele Frank handles Crinetics Pharmaceuticals as the specialist for treatments for endocrine diseases agrees to get acquired by Vertex Pharm
Comments
Sign in to join the conversation.
No comments yet. Be the first.